Jade Biosciences (JBIO) Cash & Equivalents (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Cash & Equivalents data on file, last reported at $55.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 27.69% year-over-year to $55.1 million; the trailing twelve-month figure through Mar 2026 stood at $55.1 million (down 27.69% YoY), and the FY2025 full-year result was $88.4 million, up 27.46% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $55.1 million, down from $88.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $220.9 million in Q2 2025 and bottomed at $9.1 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $32.2 million (2023), against an average of $54.9 million.
• The widest annual swing landed in 2022, when Cash & Equivalents sank 87.61%; it then surged 735.34% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $22.4 million in 2022, then gained by 4.88% to $23.5 million in 2023, then jumped by 195.37% to $69.4 million in 2024, then increased by 27.46% to $88.4 million in 2025, then sank by 37.7% to $55.1 million in 2026.
• The last three Cash & Equivalents figures came in at $55.1 million (Q1 2026), $88.4 million (Q4 2025), and $50.1 million (Q3 2025), per Business Quant data.

Peer Comparison